Home » Stocks » MYO

Myomo Inc. (MYO)

Stock Price: $10.25 USD 0.67 (6.99%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
Market Cap 46.96M
Revenue (ttm) 5.31M
Net Income (ttm) -13.30M
Shares Out 3.94M
EPS (ttm) -5.39
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $10.25
Previous Close $9.58
Change ($) 0.67
Change (%) 6.99%
Day's Open 9.58
Day's Range 9.62 - 10.88
Day's Volume 284,318
52-Week Range 3.00 - 24.50

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Business Wire - 5 days ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from...

Business Wire - 1 week ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from...

Zacks Investment Research - 1 month ago

Three currently-undervalued MedTech stocks are flourishing on the back of a few uptrends.

Other stocks mentioned: TMDX, XGN
Business Wire - 1 month ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from...

Business Wire - 2 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company offering increased functionality for individuals suffering f...

Seeking Alpha - 2 months ago

Myomo, Inc.'s (MYO) CEO Paul Gudonis on Q3 2020 Results - Earnings Call Transcript

Business Wire - 2 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from...

Business Wire - 2 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from...

Business Wire - 2 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American:MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from ...

InvestorPlace - 4 months ago

Myomo (MYO) is in the news Wednesday following an announcement about Medicare authorization that sent MYO stock soaring higher. The post Myomo News: MYO Stock Surges 32% on Medicare Authorizat...

Business Wire - 4 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Myomo, Inc.

Business Wire - 4 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Myomo, Inc.

Business Wire - 4 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Myomo, Inc.

Business Wire - 4 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Myomo, Inc.

Seeking Alpha - 5 months ago

Myomo, Inc.'s (MYO) CEO Paul Gudonis on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 5 months ago

Myomo, Inc. (MYO) delivered earnings and revenue surprises of 14.50% and 43.17%, respectively, for the quarter ended June 2020.

Business Wire - 5 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Myomo, Inc.

Business Wire - 5 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Myomo, Inc.

Seeking Alpha - 8 months ago

Myomo, Inc. (MYO) CEO Paul Gudonis on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 8 months ago

Myomo, Inc. (MYO) delivered earnings and revenue surprises of -29.38% and 29.23%, respectively, for the quarter ended March 2020.

Seeking Alpha - 10 months ago

Myomo's (MYO) CEO Paul Gudonis on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 10 months ago

Myomo, Inc. (MYO) delivered earnings and revenue surprises of -7.37% and 8.64%, respectively, for the quarter ended December 2019.

Zacks Investment Research - 10 months ago

Myomo, Inc. (MYO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Benzinga - 11 months ago

Myomo Inc (NYSE: MYO) shares ran wild Tuesday and the momentum continued in Wednesday's session.

Seeking Alpha - 1 year ago

Myomo, Inc. (MYO) CEO Paul Gudonis on Q3 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Myomo, Inc. (MYO) delivered earnings and revenue surprises of 0.00% and -53.31%, respectively, for the quarter ended September 2019.

Zacks Investment Research - 1 year ago

Myomo, Inc. (MYO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Seeking Alpha - 1 year ago

Myomo's (MYO) CEO Paul Gudonis on Q2 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Myomo, Inc. (MYO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Seeking Alpha - 1 year ago

Myomo, Inc. (MYO) CEO Paul Gudonis on Q1 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Myomo, Inc. (MYO) delivered earnings and revenue surprises of 15.00% and -3.49%, respectively, for the quarter ended March 2019.

Zacks Investment Research - 1 year ago

Myomo, Inc. (MYO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

About MYO

Myomo, a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States. The company offers MyoPro, a myoelectric-controlled upper limb brace orthosis product used for supporting a patient's weak or paralyzed arm to enable and enhance functional activities of daily living, ADLs, in the home and community. Its products are designed to help restore function in individuals with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injur... [Read more...]

Industry
Medical Devices
IPO Date
Jun 12, 2017
CEO
Paul Gudonis
Employees
49
Stock Exchange
NYSEAMERICAN
Ticker Symbol
MYO
Full Company Profile

Financial Performance

In 2019, Myomo's revenue was $3.84 million, an increase of 57.02% compared to the previous year's $2.44 million. Losses were -$10.71 million, 3.84% more than in 2018.

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for Myomo stock is "Buy." The 12-month stock price forecast is 13.81, which is an increase of 34.73% from the latest price.

Price Target
$13.81
(34.73% upside)
Analyst Consensus: Buy